Latest news with #MorphicMedical
Malaysian Reserve
05-08-2025
- Business
- Malaysian Reserve
Morphic Medical Announces CEO Transition
BOSTON, Aug. 5, 2025 /PRNewswire/ — Morphic Medical, an innovative MedTech company that has pioneered minimally invasive treatment of obesity and cardiometabolic disorders, today announced a leadership transition as part of its continued evolution and growth strategy. After 5 years of dedicated service, Joe Virgilio will be transitioning out of the role of Chief Executive Officer. Under his leadership, Morphic Medical has met several significant milestones in product development, manufacturing improvements, and organizational growth, including overseeing efforts which led to the regulatory approval of RESET® under EU MDR in July of this year. The Board of Directors is pleased to announce that Mike Gutteridge will assume the role of CEO, bringing with him a wealth of experience in the bariatric endoscopy space. Mike most recently served as Vice President of Therapy Development and Commercial Operations at Morphic where he developed the companies go-to-market strategy for RESET®. 'Joe has been instrumental in shaping Morphic Medical into the company it is today,' said Mark Lerdal, Chair of the Board of Directors. 'We are grateful for his vision, leadership, and commitment to innovation and patient care. We are equally excited to welcome Mike, who shares our values and brings a successful track record of international commercialization as we enter our next phase of growth.' 'It has been a privilege to lead Morphic Medical over the past 5 years. I am proud of what our tremendous team has accomplished and am confident in the company's future under Mike. I remain committed to the mission and look forward to supporting Mike and the Board as Morphic transitions into this exciting next chapter,' Virgilio stated. Mike Gutteridge said, 'I am honored to take on the role of Chief Executive Officer at Morphic Medical, succeeding Joe Virgilio, and I am deeply grateful for his continued support as we enter this next chapter. With over 30 years in the medtech sector spanning clinical innovation, commercial strategy, market development and reimbursement, I am energized by the opportunity to lead Morphic into its next phase, a focused expansion into global markets, accelerated commercialization, and a deepening of our commitment to improving the lives of patients through effective durable therapies. As CEO, I will build on Morphic's pioneering work in GI metabolic health and continue to foster a culture of agility, purpose, and partnership both within our exceptional team and with our growing network of clinicians, researchers, and investors. Together, we will ensure Morphic's technology reaches the people who need it most, while creating sustainable value through responsible growth. This is an exciting time for our company, and I am proud to help shape what comes next.' The leadership transition will be carefully managed over the coming months to ensure continuity across all operations, stakeholders, and partnerships. About MorphicMorphic Medical is the developer of RESET, an endoscopically delivered therapy which offers a non-surgical, alternative treatment for morbid obesity and/or obesity in the presence of concurrent cardiometabolic risk factor, e.g., type 2 diabetes and/or dyslipidemia. RESET is not approved for sale in the United States and is limited by federal law to investigational use only. Founded in 2003, Morphic Medical is headquartered in Boston, Massachusetts. For more information, please visit or follow us on Twitter and LinkedIn. Morphic Medical Media Contact:Investor Relationsinvestor@ (781) 357-3296
Yahoo
08-07-2025
- Health
- Yahoo
Morphic Medical obtains CE mark for obesity treatment
Morphic Medical has obtained an EU CE mark for RESET, a device designed to target the underlying cause of obesity and type 2 diabetes (T2D). The Boston-headquartered company's RESET is a novel duodenal-jejunal bypass liner (DJBL) that mimics the effect of gastric bypass surgery and is positioned as a less-invasive option for people with T2D and obesity who have not responded well to medications or require a 'bridge' ahead of bariatric surgery. Implanted endoscopically into the upper region of the small intestine and left in place for up to nine months, RESET creates a physical barrier between receptors in the intestinal wall and food. The approach has been demonstrated to improve weight reduction and metabolic conditions by enhancing natural hormones in the gut in a manner comparable to glucagon-like peptide-1 (GLP-1) agonists. A UK study conducted at the Sandwell and West Birmingham National Health Service (NHS) Trust demonstrated that RESET's use in individuals with diabetes and obesity resulted in an average weight reduction of 17.4kg at the three-year follow up after receiving the treatment, and a 1.9% reduction in blood glucose levels alongside improvements in blood pressure and cholesterol. Morphic Medical president and CEO, Joseph Virgilio commented: "This critical regulatory milestone is an important step toward delivering on our promise and accomplishing our mission to alleviate the symptoms of obesity and metabolic disorders such as T2D for patients fighting these global epidemics. 'We're excited to help patients who have failed to achieve their goals through a programme of diet, exercise, and medical management, and are looking for an alternative therapy.' RESET is currently only available for investigational use in the US. To support a regulatory filing with the US Food and Drug Administration (FDA), Morphic is currently enrolling patients in the STEP-1 RESET pivotal trial (NCT04101669). Planned for completion in 2026, STEP-1 is a multi-centre, randomised, sham-controlled trial that plans to enrol a total of 264 patients to evaluate the safety and effectiveness of RESET, as per the study's listing on "Morphic Medical obtains CE mark for obesity treatment" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
08-07-2025
- Health
- Yahoo
Morphic Medical obtains CE mark for obesity treatment
Morphic Medical has obtained an EU CE mark for RESET, a device designed to target the underlying cause of obesity and type 2 diabetes (T2D). The Boston-headquartered company's RESET is a novel duodenal-jejunal bypass liner (DJBL) that mimics the effect of gastric bypass surgery and is positioned as a less-invasive option for people with T2D and obesity who have not responded well to medications or require a 'bridge' ahead of bariatric surgery. Implanted endoscopically into the upper region of the small intestine and left in place for up to nine months, RESET creates a physical barrier between receptors in the intestinal wall and food. The approach has been demonstrated to improve weight reduction and metabolic conditions by enhancing natural hormones in the gut in a manner comparable to glucagon-like peptide-1 (GLP-1) agonists. A UK study conducted at the Sandwell and West Birmingham National Health Service (NHS) Trust demonstrated that RESET's use in individuals with diabetes and obesity resulted in an average weight reduction of 17.4kg at the three-year follow up after receiving the treatment, and a 1.9% reduction in blood glucose levels alongside improvements in blood pressure and cholesterol. Morphic Medical president and CEO, Joseph Virgilio commented: "This critical regulatory milestone is an important step toward delivering on our promise and accomplishing our mission to alleviate the symptoms of obesity and metabolic disorders such as T2D for patients fighting these global epidemics. 'We're excited to help patients who have failed to achieve their goals through a programme of diet, exercise, and medical management, and are looking for an alternative therapy.' RESET is currently only available for investigational use in the US. To support a regulatory filing with the US Food and Drug Administration (FDA), Morphic is currently enrolling patients in the STEP-1 RESET pivotal trial (NCT04101669). Planned for completion in 2026, STEP-1 is a multi-centre, randomised, sham-controlled trial that plans to enrol a total of 264 patients to evaluate the safety and effectiveness of RESET, as per the study's listing on "Morphic Medical obtains CE mark for obesity treatment" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
